Single-Agent Glasdegib in Patients with Myelofibrosis Previously Treated with Ruxolitinib

A Phase 2, Double-Blind, Randomized Safety and Efficacy Study of Glasdegib (PF-04449913) versus Placebo in Patients with Myelofibrosis Previously Treated with Ruxolitinib

Category & Conditions:
Cancer
Medicine:
DAURISMO TABLETS(GLASDEGIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B1371013
Open Plain Language Summary Result:Click here